Amgen Presents Detailed Data Comparing Etelcalcetide With Cinacalcet In Patients With Secondary Hyperparathyroidism Receiving Hemodialysis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. GOOGL
5. APGE
6. MU
7. DFTX
8. LLY
9. RGNX
10. LCO

Go back to Amgen Presents Detailed Data Comparing Etelcalcetide With Cinacalcet In Patients With Secondary Hyperparathyroidism Receiving Hemodialysis

Cytokinetics (CYTK) and Amgen Inc. (AMGN) Announce COSMIC-HF Data; Roth Capital Raises Price Target to $22

November 9, 2015 7:32 AM EST

Roth Capital maintained a Buy rating on Cytokinetics (NASDAQ: CYTK), and raised the price target to $22.00 (from $18.00), following announced full data from COSMIC-HF at AHA. The large data set was announced jointly by Cytokinetics and global partner Amgen (NASDAQ:... More